A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

NCT06340958 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Adjunctive Treatment of Major Depressive Disorder (MDD)

Interventions

DRUG: CLE-100
DRUG: Placebo

Sponsor

Clexio Biosciences Ltd.